Study #2021-0358
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (JZP598) in Patients with Early Stage HER2/neu Positive (HER2+) Breast Cancer (BC) NeoZanHER
MD Anderson Study Status
Enrolling
Treatment Agent
Zanidatamab, Letrozole, Tamoxifen
Description
This is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determine the efficacy of zanidatamab for patients with early stage HER2/neu positive (HER2+) breast cancer (BC) as determined by pathologic complete response (pCR) .
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer, HER2-positive
Study phase:
Phase II
Physician name:
Vicente Valero
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-844-285-5619
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.